Clinical trials in gynecologic oncology: Past, present, and future.

about

Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives

P2860

Q57174233-68D86EB0-F52E-4B5D-B399-BA6ED0BAE6E1

P2860

Clinical trials in gynecologic oncology: Past, present, and future.

Item

http://www.wikidata.org/entity/Q47796770

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Clinical trials in gynecologic oncology: Past, present, and future.

@en

Clinical trials in gynecologic oncology: Past, present, and future.

@nl

type

Item

label

Clinical trials in gynecologic oncology: Past, present, and future.

@en

Clinical trials in gynecologic oncology: Past, present, and future.

@nl

prefLabel

Clinical trials in gynecologic oncology: Past, present, and future.

@en

Clinical trials in gynecologic oncology: Past, present, and future.

@nl

P1476

Clinical trials in gynecologic oncology: Past, present, and future.

@en

P2093

Elise C Kohn

http://www.w3.org/2001/XMLSchema#string

P2860

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An

A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).

A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study

A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.

A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study.

A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study

A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study

A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynec

Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.

Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.

P304

393-402

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1016/J.YGYNO.2017.11.026

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

148

http://www.w3.org/2001/XMLSchema#string

P50

Christina M Annunziata

P577

2017-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29212614

http://www.w3.org/2001/XMLSchema#string

P932

5801214

http://www.w3.org/2001/XMLSchema#string

Clinical trials in gynecologic oncology: Past, present, and future.

about

P2860

P2860

Clinical trials in gynecologic oncology: Past, present, and future.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932